Abstract
Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor that activates downstream signaling pathways, including the Ras-MEK-Erk and PI3K-AKT pathways, leading to cell proliferation, resistance to apoptosis, angiogenesis and the ability to metastasize. EGFR overexpression is a significant finding in cancer, particularly in head and neck cancer, where it is also associated with a poor prognosis. In recent years, several molecules have been designed to inhibit EGFR activation. Among the many available anti-EGFR drugs, only cetuximab was approved for the treatment of head and neck cancers. However, no predictive biomarkers of cetuximab response are currently known. In the present review, we provide an updated assessment of EGFR biology and its clinical impact in head and neck cancers. A special emphasis is placed on novel patents of EGFR-inhibitors that are anticipated to diversify the anti-EGFR therapies available to treat head and neck cancers. In particular, we outline a new class of irreversible multi-target inhibitors (e.g. afatinib, icotinib, CUDC-101), which may significantly contribute to new head and neck cancer therapies.
Keywords: Anti-EGFR patents, EGFR, EGFR overexpression, head and neck squamous cell carcinoma, tyrosine kinase inhibtors, targeted therapies.
Recent Patents on Anti-Cancer Drug Discovery
Title:Anti-EGFR Therapy: Strategies in Head and Neck Squamous Cell Carcinoma
Volume: 11 Issue: 2
Author(s): Renato J. Oliveira-Silva, Ana Carolina de Carvalho, Luciano de Souza Viana, Andre L. Carvalho and Rui M. Reis
Affiliation:
Keywords: Anti-EGFR patents, EGFR, EGFR overexpression, head and neck squamous cell carcinoma, tyrosine kinase inhibtors, targeted therapies.
Abstract: Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor that activates downstream signaling pathways, including the Ras-MEK-Erk and PI3K-AKT pathways, leading to cell proliferation, resistance to apoptosis, angiogenesis and the ability to metastasize. EGFR overexpression is a significant finding in cancer, particularly in head and neck cancer, where it is also associated with a poor prognosis. In recent years, several molecules have been designed to inhibit EGFR activation. Among the many available anti-EGFR drugs, only cetuximab was approved for the treatment of head and neck cancers. However, no predictive biomarkers of cetuximab response are currently known. In the present review, we provide an updated assessment of EGFR biology and its clinical impact in head and neck cancers. A special emphasis is placed on novel patents of EGFR-inhibitors that are anticipated to diversify the anti-EGFR therapies available to treat head and neck cancers. In particular, we outline a new class of irreversible multi-target inhibitors (e.g. afatinib, icotinib, CUDC-101), which may significantly contribute to new head and neck cancer therapies.
Export Options
About this article
Cite this article as:
J. Oliveira-Silva Renato, Carolina de Carvalho Ana, de Souza Viana Luciano, L. Carvalho Andre and M. Reis Rui, Anti-EGFR Therapy: Strategies in Head and Neck Squamous Cell Carcinoma, Recent Patents on Anti-Cancer Drug Discovery 2016; 11 (2) . https://dx.doi.org/10.2174/1574892811666160309121238
DOI https://dx.doi.org/10.2174/1574892811666160309121238 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Monoclonal Antibodies as Cancer Therapeutics
Recent Patents on Biotechnology The Clustered DNA Lesions – Types, Pathways of Repair and Relevance to Human Health
Current Medicinal Chemistry Combined Cancer Therapy with Non-Conventional Drugs: All Roads Lead to AMPK
Mini-Reviews in Medicinal Chemistry Phytochemicals as Adjunctive with Conventional Anticancer Therapies
Current Pharmaceutical Design Multifuntional Nanoparticles: Preparation and Applications in Biomedicine and in Non-Invasive Bioimaging
Recent Patents on Nanotechnology Antigen-specific Immunotherapy in Ovarian Cancer and p53 as Tumor Antigen
Current Pharmaceutical Design Are Vegetables, Salads, Herbs, Mushrooms, Fruits and Red Wine Residue that Inhibit Bone Resorption in the Rat a Promise of Osteoporosis Prevention?
Current Nutrition & Food Science The Radionuclide Molecular Imaging and Therapy of Neuroendocrine Tumors
Current Cancer Drug Targets A Review on Structures and Functions of Bcl-2 Family Proteins from Homo sapiens
Protein & Peptide Letters Signal Transducer and Activator of Transcription 3 Signaling Pathway: A Potential Target in Sarcoma Treatment
Current Enzyme Inhibition Roles of Natural Compounds from Medicinal Plants in Cancer Treatment: Structure and Mode of Action at Molecular Level
Medicinal Chemistry Epigenetic Interventions Increase the Radiation Sensitivity of Cancer Cells
Current Pharmaceutical Design Editorial (Thematic Issue: Targeted Anti-Cancer Drug Delivery)
Current Cancer Drug Targets Electrochemotherapy as First Line Cancer Treatment: Experiences from Veterinary Medicine in Developing Novel Protocols
Current Cancer Drug Targets Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy
Current Signal Transduction Therapy Meet Our Editorial Board Member
Current Cancer Therapy Reviews Pregnane X Receptor and its Potential Role in Drug Resistance in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Targeting the Folate Receptor: Improving Efficacy in Inorganic Medicinal Chemistry
Current Medicinal Chemistry Volatilome Metabolomics and Databases, Recent Advances and Needs
Current Metabolomics Polymeric Nanoparticles of FMISO: Are Nano-Radiopharmaceuticals Better Than Conventional Ones?
Current Radiopharmaceuticals